专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011122022A1 ECT2 PEPTIDES AND VACCINES INCLUDING THE SAME 审中-公开
标题翻译： ECT2肽和疫苗，包括它们
公开(公告)号：WO2011122022A1
公开(公告)日：2011-10-06
申请号：PCT/JP2011/001909
申请日：2011-03-30
申请人： ONCOTHERAPY SCIENCE, INC. , NAKAMURA, Yusuke , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
发明人： NAKAMURA, Yusuke , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
IPC分类号： C12N15/09
CPC分类号： C07K7/06 , A61K39/0011 , A61K2039/572
摘要： Isolated peptides derived from SEQ ID NO: 42 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the afore- mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophageal cancer, NSCLC, lymphoma, pancreatic cancer, prostate cancer, renal carcinoma and SCLC.
摘要翻译：衍生自SEQ ID NO：42的分离的肽及其与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的片段，因此适用于癌症免疫治疗，特别是癌症疫苗的上下文中。本发明的肽包括上述氨基酸序列及其修饰形式，其中一个，两个或几个氨基酸被取代，缺失，插入或添加，只要这些修饰版本保留所需的HLA结合和/或CTL诱导性的原始序列。还提供了编码任何前述肽的核酸以及包括或掺入任何前述肽或核酸的药物，物质和/或组合物。本发明的肽，核酸，药物，物质和组合物在治疗癌症和肿瘤方面特别有用，包括例如膀胱癌，乳腺癌，子宫颈癌，胆管细胞癌，CML，结肠直肠癌，食管癌，NSCLC，淋巴瘤，胰腺癌，前列腺癌，肾癌和SCLC。

2. 发明申请

WO2011111392A1 HJURP PEPTIDES AND VACCINES INCLUDING THE SAME 审中-公开
标题翻译： HJURP肽和疫苗，包括它们
公开(公告)号：WO2011111392A1
公开(公告)日：2011-09-15
申请号：PCT/JP2011/001407
申请日：2011-03-10
申请人： ONCOTHERAPY SCIENCE, INC. , NAKAMURA, Yusuke , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
发明人： NAKAMURA, Yusuke , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
IPC分类号： C12N15/09 , A61K35/00 , A61K38/00 , C07K7/06 , C07K16/18 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/00 , C12N5/10
CPC分类号： C07K14/4748 , A61K35/12 , A61K38/00 , A61K39/00 , C07K7/06 , C07K16/18
摘要： Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids sequences substituted, deleted, added or inserted, provided such modified versions retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, Diffused-type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor.
摘要翻译：衍生自SEQ ID NO：50的分离的肽及其与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的片段，因此适用于癌症免疫治疗的上下文，更具体地，本文描述了癌症疫苗。本发明的肽包括上述氨基酸序列及其修饰形式，其中一个，两个或几个氨基酸序列被取代，缺失，添加或插入，只要这些修饰形式保留原始序列的必需细胞毒性T细胞诱导性。还提供了编码任何前述肽的核酸以及包括或掺入任何前述肽或核酸的药物，物质和/或组合物。本发明的肽，核酸，药物，物质和组合物特别用于治疗癌症和肿瘤，包括例如AML，膀胱癌，乳腺癌，宫颈癌，胆管细胞癌，CML，结肠直肠癌，食管癌，扩散型胃癌，肝癌，NSCLC，淋巴瘤，骨肉瘤，卵巢癌，胰腺癌，前列腺癌，肾癌，SCLC，软组织肿瘤和睾丸肿瘤。

3. 发明申请

WO2011125139A1 CLUAP1 PEPTIDES AND VACCINES INCLUDING THE SAME 审中-公开
标题翻译： CLUAP1包括其中的肽和疫苗
公开(公告)号：WO2011125139A1
公开(公告)日：2011-10-13
申请号：PCT/JP2010/006313
申请日：2010-10-26
申请人： ONCOTHERAPY SCIENCE, INC. , NAKAMURA, Yusuke , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
发明人： NAKAMURA, Yusuke , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
IPC分类号： C07K7/06 , A61K39/00 , A61P35/00 , C07K14/705 , C07K16/00 , C12N5/10 , C12N15/00
CPC分类号： C07K14/4748 , A61K39/0011 , G01N2333/47 , G01N2333/775
摘要： Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the CLUAP1 gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing as active ingredient peptides derived from CLUAP1 or polynucleotides encoding the peptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors), and/or the prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from CLUAP1, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.
摘要翻译：本文描述了针对癌症的肽疫苗。特别地，提供了衍生自引起CTL的CLUAP1基因的表位肽。还提供抗原呈递细胞和靶向这些肽的分离的CTL以及诱导抗原呈递细胞或CTL的方法。本发明还提供了含有作为活性成分的衍生自CLUAP1的肽或编码肽作为活性成分的多核苷酸的药物组合物。此外，本发明提供了治疗和/或预防（即预防）癌症（肿瘤）和/或预防其术后复发的方法，以及诱导CTL的方法，诱导抗肿瘤免疫的方法，使用衍生自CLUAP1的肽，编码肽的多核苷酸或呈递肽的抗原呈递细胞，或本发明的药物组合物。

4. 发明申请

WO2010131452A1 TTK PEPTIDES AND VACCINES INCLUDING THE SAME 审中-公开
标题翻译： TTK肽和疫苗，包括它们
公开(公告)号：WO2010131452A1
公开(公告)日：2010-11-18
申请号：PCT/JP2010/003166
申请日：2010-05-10
申请人： ONCOTHERAPY SCIENCE, INC. , NAKAMURA, Yusuke , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
发明人： NAKAMURA, Yusuke , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
IPC分类号： C07K7/06 , A61K38/00 , A61P35/00 , C07K16/18 , C12N15/09
CPC分类号： A61K39/0011 , A61K38/00 , A61K2039/572 , C07K14/4748
摘要： Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the TTK gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing as active ingredients peptides derived from TTK or polynucleotides encoding the peptides. Furthermore, the present invention provides methods for the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors), and/or the prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from TTK, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.
摘要翻译：本文描述了针对癌症的肽疫苗。特别地，提供了衍生自引起CTL的TTK基因的表位肽。还提供抗原呈递细胞和靶向这些肽的分离的CTL以及诱导抗原呈递细胞或CTL的方法。本发明还提供含有作为活性成分的衍生自TTK的肽或编码肽的多核苷酸的药物组合物。此外，本发明提供了治疗和/或预防（即预防）癌症（肿瘤）和/或预防其术后复发的方法，以及诱导CTL的方法，诱导抗肿瘤免疫的方法，使用衍生自TTK的肽，编码肽的多核苷酸或呈递肽的抗原呈递细胞，或本发明的药物组合物。

5. 发明申请

WO2011125334A1 CDCA5 PEPTIDES AND VACCINES INCLUDING THE SAME 审中-公开
标题翻译： CDCA5肽和疫苗，包括它们
公开(公告)号：WO2011125334A1
公开(公告)日：2011-10-13
申请号：PCT/JP2011/002078
申请日：2011-04-07
申请人： ONCOTHERAPY SCIENCE, INC. , NAKAMURA, Yusuke , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
发明人： NAKAMURA, Yusuke , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
IPC分类号： C07K7/06 , C12N5/0781 , C12N5/0783 , C12N5/10 , C12N15/09
CPC分类号： C07K7/06 , A61K38/00 , C07K14/4738
摘要： Isolated peptides derived from SEQ ID NO: 21 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, gastric cancer, gastric diffuse-type cancer, lung cancer, lymphoma, prostate cancer, SCLC and soft tissue tumor.
摘要翻译：本文描述了衍生自SEQ ID NO：21的分离的肽及其与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的片段，因此适用于癌症免疫治疗，特别是癌症疫苗的上下文中。本发明的肽包括上述氨基酸序列及其修饰形式，其中一个，两个或若干个氨基酸被取代，缺失，插入或添加，只要这些修饰版本保持必需的HLA结合和/或CTL诱导性原始序列。还提供了编码任何前述肽的核酸以及包括或掺入任何前述肽或核酸的药物，物质和/或组合物。本发明的肽，核酸，药物，物质和组合物特别用于治疗癌症和肿瘤，包括例如AML，膀胱癌，乳腺癌，宫颈癌，胆管细胞癌，CML，结肠直肠癌，食管癌，胃癌，胃弥漫型癌，肺癌，淋巴瘤，前列腺癌，SCLC和软组织肿瘤。

6. 发明申请

WO2011089921A1 MODIFIED MELK PEPTIDES AND VACCINES CONTAINING THE SAME 审中-公开
标题翻译：改良的梅毒肽和含有其的疫苗
公开(公告)号：WO2011089921A1
公开(公告)日：2011-07-28
申请号：PCT/JP2011/000352
申请日：2011-01-24
申请人： ONCOTHERAPY SCIENCE, INC. , NAKAMURA, Yusuke , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
发明人： NAKAMURA, Yusuke , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
IPC分类号： C07K7/06 , A61K38/00 , A61P35/00
CPC分类号： C12Y207/11025 , A61K39/0011 , A61K39/39 , C12N9/1205
摘要： Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild type MELK epitope peptide and thus are suitable for use in the context of cancer immunotherapy or endometriosis immunotherapy, more particularly cancer or endometriosis vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical substances and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical substances and compositions of this invention find particular utility in the treatment of cancers, tumors, and endometriosis.
摘要翻译：由修饰的MELK表位肽或其免疫活性片段的氨基酸序列组成的分离肽，其结合HLA抗原并且具有比野生型MELK表位肽更高的细胞毒性T淋巴细胞（CTL）诱导性，因此适用于本文描述了癌症免疫治疗或子宫内膜异位症免疫治疗的背景，更特别的是癌症或子宫内膜异位症疫苗。本发明进一步提供了肽，其包括前述肽或片段的一个，两个或几个氨基酸插入，取代或添加，但仍保留所需的细胞毒性T细胞诱导性。进一步提供编码任何这些上述肽的核酸以及包含上述肽或核酸中任何一种的药物和组合物。本发明的肽，核酸，药物和组合物在癌症，肿瘤和子宫内膜异位症的治疗中特别有用。

7. 发明申请

WO2010106770A1 NEIL3 PEPTIDES AND VACCINES INCLUDING THE SAME 审中-公开
标题翻译： NEIL3肽和疫苗，包括它们
公开(公告)号：WO2010106770A1
公开(公告)日：2010-09-23
申请号：PCT/JP2010/001808
申请日：2010-03-15
申请人： ONCOTHERAPY SCIENCE, INC. , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa , NAKAMURA, Yusuke , FURUKAWA, Yoichi
发明人： TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa , NAKAMURA, Yusuke , FURUKAWA, Yoichi
IPC分类号： C12N15/09 , A61K39/00 , A61P35/00 , C07K7/06 , C07K14/705
CPC分类号： C07K14/4748 , A61K39/00 , A61K39/0011 , A61K39/39 , A61K2039/53 , A61K2039/572 , C12N9/88 , C12Y402/99018 , Y02A50/396
摘要： The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.
摘要翻译：本发明提供分离的肽或衍生自SEQ ID NO：45的片段，其结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL）。肽可以包括具有取代缺失的上述氨基酸序列，或加入一个，两个或几个氨基酸序列。本发明还提供了包括这些肽的药物组合物。本发明的肽可用于诊断或治疗癌症。

8. 发明申请

WO2011074236A1 TMEM22 PEPTIDES AND VACCINES INCLUDING THE SAME 审中-公开
标题翻译： TMEM22肽和疫苗，包括它们
公开(公告)号：WO2011074236A1
公开(公告)日：2011-06-23
申请号：PCT/JP2010/007228
申请日：2010-12-13
申请人： ONCOTHERAPY SCIENCE, INC. , NAKAMURA, Yusuke , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
发明人： NAKAMURA, Yusuke , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
IPC分类号： C07K7/06 , C12N5/0781 , C12N5/0783 , C12N5/10 , C12N15/09
CPC分类号： C07K7/06 , A61K39/00 , A61K39/0011 , A61K2039/57 , C07K14/705
摘要： Isolated peptides composed of the amino acid sequence of SEQ ID NO: 33 or fragments thereof that bind to HLA antigens and have cytotoxic T lymphocyte (CTL) inducibility and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical agents, substances and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors.
摘要翻译：描述了由SEQ ID NO：33的氨基酸序列组成的分离肽或其与HLA抗原结合并具有细胞毒性T淋巴细胞（CTL）诱导性的因此适合用于癌症免疫治疗，特别是癌症疫苗的上下文中的其片段于此。本发明进一步提供了肽，其包括前述肽或片段的一个，两个或几个氨基酸插入，取代或添加，但仍保留所需的细胞毒性T细胞诱导性。还提供了编码任何上述肽的核酸以及包含上述肽或核酸中任何一种的药物，物质和组合物。本发明的肽，核酸，药物，物质和组合物在癌症和肿瘤的治疗中具有特别的用途。

9. 发明申请

WO2011067933A1 MYBL2 PEPTIDES AND VACCINES CONTAINING THE SAME 审中-公开
标题翻译： MYBL2 PEPTIDES和含有它的疫苗
公开(公告)号：WO2011067933A1
公开(公告)日：2011-06-09
申请号：PCT/JP2010/007028
申请日：2010-12-02
申请人： ONCOTHERAPY SCIENCE, INC. , NAKAMURA, Yusuke , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
发明人： NAKAMURA, Yusuke , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
IPC分类号： C07K7/06 , A61K39/00 , A61P35/00 , C12N15/09
CPC分类号： C07K14/82 , A61K39/0011 , C07K14/4748
摘要： Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the MYBL2 gene that bind to HLA antigen and have cytotoxic T lymphocyte (CTL) inducibility, more particularly peptides having the amino acid sequence of SEQ ID NO: 5 and fragments thereof, are provided. The present invention further extends to peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, provided they retain cytotoxic T cell inducibility. Also provided as nucleic acids encoding any of the aforementioned peptides, antigen-presenting cells and isolated CTLs that target such peptides, and pharmaceutical agents and compositions including any of the aforementioned peptides, nucleic acids, and APCs as active ingredients. The components of the present invention have particular utility in connection with the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors), and/or the prevention of a postoperative recurrence thereof.
摘要翻译：本文描述了针对癌症的肽疫苗。特别地，提供了衍生自结合HLA抗原并具有细胞毒性T淋巴细胞（CTL）诱导能力的MYBL2基因的表位肽，更特别是具有SEQ ID NO：5的氨基酸序列及其片段的肽。本发明进一步延伸到包括前述肽或片段的一个，两个或几个氨基酸插入，取代或添加的肽，条件是它们保留细胞毒性T细胞诱导性。还提供了编码任何上述肽，抗原呈递细胞和靶向这些肽的分离的CTL的核酸以及包含任何上述肽，核酸和APC作为活性成分的药物和组合物的核酸。本发明的组分与癌症（肿瘤）的治疗和/或预防（即预防）和/或预防其术后复发有关。

10. 发明申请

WO2010113495A1 C6ORF167 PEPTIDES AND VACCINES CONTAINING THE SAME 审中-公开
标题翻译： C6ORF167肽及其含有的疫苗
公开(公告)号：WO2010113495A1
公开(公告)日：2010-10-07
申请号：PCT/JP2010/002352
申请日：2010-03-31
申请人： ONCOTHERAPY SCIENCE, INC. , NAKAMURA, Yusuke , DAIGO, Yataro , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
发明人： NAKAMURA, Yusuke , DAIGO, Yataro , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
IPC分类号： C07K7/06 , A61K39/00 , A61P35/00 , C07K14/82 , C07K16/32 , C12N15/09 , C12Q1/04 , C12Q1/68 , G01N33/50 , G01N33/574
CPC分类号： G01N33/57407 , A61K39/0011 , C12Q1/6886 , C12Q2600/112
摘要： Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the C6orf167 gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing peptides derived from C6orf167 or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from C6orf167, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.
摘要翻译：本文描述了针对癌症的肽疫苗。特别地，提供了衍生自引起CTL的C6orf167基因的表位肽。还提供抗原呈递细胞和靶向这些肽的分离的CTL以及诱导抗原呈递细胞或CTL的方法。本发明还提供含有衍生自C6orf167的肽或编码多肽作为活性成分的多核苷酸的药物组合物。此外，本发明提供了治疗和/或预防（即预防）癌症（肿瘤）和/或预防其术后复发的方法，以及诱导CTL的方法，诱导抗肿瘤免疫的方法，使用衍生自C6orf167的肽，编码肽的多核苷酸或呈递肽的抗原呈递细胞，或本发明的药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式